BioCentury
ARTICLE | Clinical News

Cavatak: Preliminary Ph Ib data

November 10, 2016 11:25 PM UTC

Preliminary data from 17 evaluable patients with ≥1 injectable lesion in the open-label, U.S. Phase Ib MITCI trial showed that intratumoral Cavatak plus Yervoy ipilimumab led to an ORR of 52.9%, inclu...